KAEL-GemVax reports encouraging interim progress in Phase II study of GV1001 ... MarketWatch (press release) The authors found the high immunologic response rate indicated that the vaccine may be useful for the general patient population without prior HLA typing. Moreover, long-term T-cell memory against telomerase antigens was induced without compromising ... |
